IBB241206P90000
- 0.00
- 0.000.00%
iShares Biotechnology ETF Newsroom
Which Stocks Could Join the Nasdaq 100? Palantir and MicroStrategy Lead the List
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Powell Speech
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
Looking At Gilead Sciences's Recent Unusual Options Activity
European Stocks Will See Downtrend Mid-year 2025 Before Recovery
Tuesday S&P 500 Pulls Back From Highs, Nasdaq Climbs | Live Stock
Sector Update: Health Care Stocks Decline Premarket Tuesday
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Ahead of October JOLTS Report
S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today
Gilead Sciences Ticks Upward for the Eight Consecutive Session
10 Health Care Stocks With Whale Alerts In Today's Session
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
December Starts With a Mixed Market | Live Stock
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday Ahead of Week Promising Crucial Economic Data
The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?
Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.
Barclays's 'Bang-for-the-buck' Tail Hedging ETFs: HYG, XLF, IYR